Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

Traumatic Brain Injury Clinical Trial

Official title:

Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05616910
• Other study ID #: 851809
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2024
• Est. completion date: August 31, 2027

Study information

• Verified date: May 2024
• Source: University of Pennsylvania
• Contact: Samuel Shin
• Phone: 267-734-3042
• Email: samuel.shin[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Traumatic brain injury (TBI) causes acute deficits in cerebral perfusion which may lead to secondary injury and worse outcomes. Inhaled nitric oxide (iNO) is a vasodilator that increases cerebral blood flow and is clinically used for hypoxic respiratory failure in neonates and adults. The investigators will perform a randomized controlled trial of iNO treatment in TBI patients acutely after injury. The investigators will then assess perfusion changes with optic neuromonitoring, blood biomarkers, and 6 month clinical outcomes.

Description:

The objective of this study is to show that inhaled nitric oxide can increase blood flow in the brain after traumatic brain injury, attenuating brain injury and resulting in improved long-term function.

The investigators will use optical brain monitoring to determine changes in cerebral perfusion and metabolism by iNO treatment in TBI subjects. Within 24 hours of enrollment, TBI subjects meeting the inclusion criteria without exclusion criteria will undergo 8 hour sessions of monitoring (4 hours on iNO, 4 hours on standard respiratory therapy) for 3 days. During this time, Noninvasive Neuro-optic Monitoring (NNOM) device will be placed on the scalp and cerebral perfusion and metabolism parameters will be monitored to assess for therapeutic effect of iNO. There will be within-subject comparison of cerebral perfusion and metabolism on and off iNO. Also, there will be within-group comparison of cerebral perfusion and metabolism on days when iNO is given first vs days when iNO is given at a second session. Additionally, these parameters from this group will compared to a parallel group of TBI patients receiving 8 hours of only standard respiratory therapy for 3 days.

The investigators will assess the safety profile of iNO use in TBI subjects. During the course of iNO therapy in the initial 3 days, study subjects will be monitored for methemoglobinemia, hypotension, neurological exam changes, and any other adverse events. These outcomes will be monitored for 2 weeks following the iNO treatment. Additionally, the investigators will assess blood-based biomarkers of injury with blood draws at the end of each iNO treatment session in TBI subjects for 3 days. During the initial three days of the trial, blood draws will be performed at the end of each session to detect biomarkers. Specifically, biomarkers that have been shown to correlate with injury severity such as GFAP, NFL, UCHL-1, tau, and S100B will be monitored at the end of iNO session and standard respiratory therapy session. This will be performed by using a novel assay termed SIMOA, a sensitive detection method for blood-based biomarkers.

As an exploratory aim, the investigators will compare 6-month GOS-E outcomes of the patients who received iNO to those who received standard respiratory therapy. Patients will be assessed for their functional status at the time of 6 month follow up. Each patient in this study will be compared to a patient who had similar demographic background, mechanism of injury (fall, motor vehicle crash, assault), and severity of injury (based on Glasgow Coma Scale) from an existing database.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 38
• Est. completion date: August 31, 2027
• Est. primary completion date: August 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 (inclusive)

2. Male or Female

3. GCS 9-12 or GCS 13-15 with an abnormal imaging scan

4. Loss of consciousness for 30 minutes to 24 hours

5. Post traumatic amnesia 1 day

6. Radiologic findings indicative of primarily diffuse TBI

7. Both Intubated and nonintubated patients

Exclusion Criteria:

1. Severe cardiac dysfunction (e.g. elevation of pulmonary edema on chest xray, large elevation of cardiac enzymes)

2. Large focal injury (subdural hematoma, epidural hematoma, intraparenchymal hematoma 30mL aggregate volume)

3. Need for immediate neurosurgical intervention

4. Pre-existing disabling psychiatric or neurological disorders such as cortical stroke, brain tumor, disabling multiple sclerosis, dementia, and severe TBI

5. Known intracranial large vessel disease

6. Acute Respiratory Distress Syndrome (ARDS) or pre-existing pulmonary hypertension

7. Cardiopulmonary resuscitation or cardioversion at admission

8. Chronic Kidney Disease (Glomerular Filtration Rate 60mL/min/1.73m2)

9. Respiratory infection

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Traumatic Brain Injury
• Wounds and Injuries

Intervention

Drug:
• inhaled nitric oxide
iNO will be provided by ventilator or nasal cannula for 4 hours each day.

Locations

Country	Name	City	State
United States	Penn Presbyterian Medical Center	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cerebral Metabolism assessed by Spectroscopy	Metabolic Rate of oxygen consumption by the brain measured by diffuse correlation spectroscopy and time-resolved infrared-spectroscopy.	3 days
Secondary	Incidence of Inhaled Nitric Oxide induced methemoglobinemia	Methemoglobin levels of blood greater than 1%	14 days
Secondary	Incidence of Inhaled Nitric Oxide induced hypotension	Blood pressure less than 90/60 mmHg for 30 minutes or longer	14 days
Secondary	Incidence of Inhaled Nitric Oxide induced neurological deterioration	Glasgow coma scale decrease of 2 or more points.	14 days
Secondary	Blood-based biomarkers of injury	Levels of neurofilament-light, glial fibrillary acidic protein, tau, ubiquitin carboxy-terminal hydrolase L1 (all biomarkers are in units of pg/mL)	3 days
Secondary	Long term functional outcome	Glasgow Outcome Scale Extended (GOS-E) (range: 1-8, 1: death, 8: good recovery).	6 months